跳转至内容
Merck
CN

Ampicillin use in infant fever: a systematic review.

Archives of pediatrics & adolescent medicine (2002-01-12)
Julie C Brown, Jane L Burns, Peter Cummings
摘要

To estimate the prevalence of perinatal Listeria monocytogenes and enterococcal infections in outpatient febrile infants and to evaluate the need to treat with ampicillin. Online bibliographies were searched for articles related to serious bacterial infection and fever in infants. Reference lists from selected and review articles were also examined. Studies that reported rates and types of bacterial infection in febrile outpatients younger than 3 months were included. Those performed outside North America, lacking results by age, or those that evaluated selected patient populations were excluded. Two authors independently reviewed the selected articles for inclusion and abstracted the data. Fourteen studies, evaluating 5247 febrile outpatients, were included. The prevalences of L monocytogenes and enterococcal infections were 7.3 (binomial exact 95% confidence interval [CI], 3.5-13.3), 1.9 (95% CI, 0.6-4.4), and 5.6 (95% CI, 0.7-2.1) per 1000 febrile infants in the first, second, and third months of life, respectively. To cover 1 infant with serious bacterial infection caused by L monocytogenes and enterococcal infections, the numbers of febrile infants who would need ampicillin were estimated as 138 (95% CI, 76-288) in the first month, 527 (95% CI, 226-1621) in the second month, and 178 (95% CI, 50-1469) in the third month. Enterococcal infections occurred in all ages studied; there were no Listeria infections after 30 days of age. The empirical use of ampicillin to cover febrile infants for L monocytogenes and enterococcal infections is most justifiable in the first month of life.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氨苄西林, anhydrous, 96.0-102.0% (anhydrous basis)
Supelco
氨苄西林
USP
氨苄西林, United States Pharmacopeia (USP) Reference Standard
氨苄西林, anhydrous, European Pharmacopoeia (EP) Reference Standard